Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dong-lai LV"'
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2569e60abaaf49566762914585e54e47
http://europepmc.org/articles/PMC8040179
http://europepmc.org/articles/PMC8040179
Publikováno v:
Anti-cancer drugsReference. 33(1)
No targeted therapies are approved for non-small-cell lung cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation to date. Trametinib, a selective allosteric inhibitor of the MEK1/2, demonstrated debatable clinical activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59607e4cd0e31efcea3bdeb5e2d4fee5
https://pubmed.ncbi.nlm.nih.gov/34387588
https://pubmed.ncbi.nlm.nih.gov/34387588
Background: Detection of anaplastic lymphoma kinase (ALK) gene rearrangements is an important step in the selection of effective therapies for patients with advanced lung adenocarcinoma. However, there have been few reports of ALK‐positive lung squ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::104cd28ca26bb7d9e293200378906f79
https://doi.org/10.21203/rs.3.rs-454727/v1
https://doi.org/10.21203/rs.3.rs-454727/v1
Autor:
Ying Liu1,2 rainlaw2005@163.com, Dong-lai Lv1,2 lvxunhuan@163.com, Jiang-jie Duan1,2 duanjiangjie@qq.com, Sen-lin Xu1,2 xusenlin@gmail.com, Jing-fang Zhang3 zhangjf06@gmail.com, Xiao-jun Yang1,2 xiaojunyang.cn@gmail.com, Xia Zhang1,2 zhangxia45@yahoo.com, You-hong Cui2 cuiyouhongx@yahoo.com, Xiu-wu Bian1,2 bianxiuwu@263.net, Shi-cang Yu1,2 yushicang@163.com
Publikováno v:
BMC Cancer. 2014, Vol. 14 Issue 1, p1-22. 22p.
Publikováno v:
Medical Journal of Chinese People's Liberation Army, Vol 37, Iss 7, Pp 559-562 (2012)
Objective To evaluate the therapeutic efficacy of whole-brain radiotherapy (WBRT) alone or in combination with stereotactic radiotherapy (SRT) in patients with brain metastasis. Methods Literatures related to therapeutic efficacy comparison of WBRT+S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::2b34be519bab84ba1b6696485185912d
http://www.plamj.org/index.php/plamj/article/view/520
http://www.plamj.org/index.php/plamj/article/view/520
Publikováno v:
Cancer letters. 377(1)
Fluorescence-activated cell sorting (FACS) based on the surface marker CD133 is the most common method for isolating glioma stem cells (GSCs) from heterogeneous glioma cell populations. Optimization of this method will have profound implications for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42a8e2d87c06b5fac524c0b170681c0
https://pubmed.ncbi.nlm.nih.gov/27091400
https://pubmed.ncbi.nlm.nih.gov/27091400
Autor:
Shi-cang Yu, You-Hong Cui, Ying Liu, Jing-fang Zhang, Xia Zhang, Sen-Lin Xu, Jiang-jie Duan, Dong-lai Lv, Xiao-jun Yang, Xiu-Wu Bian
Publikováno v:
BMC Cancer
Background Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) has been identified as a putative cancer stem cell (CSC) marker in breast cancer. However, the clinicopathological and prognostic significance of this protein in breast cancer patients re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32c499b2a1eb80c35a45f4f5030908f5
https://doi.org/10.1186/1471-2407-14-444
https://doi.org/10.1186/1471-2407-14-444